Based on the study of the SNVs landscape of Ras GTPase-activating proteins in various cancer samples, the following key conclusions can be drawn: In multiple cancers, including endometrial carcinoma, skin melanoma, lung squamous cell carcinoma, stomach adenocarcinoma, colorectal adenocarcinoma, lung adenocarcinoma, and rectal adenocarcinoma, five Ras GTPase-activating proteins exhibited a high mutation frequency. This evidence concerns the gene RASA2 and endometrial carcinoma.